CPhI Announces 2014 Expert Industry Panel

PR56644

AMSTERDAM, May 1, 2014/PRN=KYODO JBN/--

    - Panel to contribute to Pharma Insights reports and second addition of the

CPhI annual report due to be launched at CPhI Worldwide 2014

    Panel members for 2014:

    - Prabir Basu, President at Pharma Manufacturing

    - Girish Malhotra, President & Founder, Epcot International       

[http://www.pharmaevolution.com/bloggers.asp#Girish_Malhotra ]

    - Hedley Rees, Managing Director at PharmaFlow Ltd

    - Ajaz Hussain, CSO & President Biotechnology at Wockhardt

    - Sam Venugopal, Director in the Healthcare Practice at PWC

    - William Botha, Consultant and Founder Interlean

    - Emil Ciurczak, President at Doramaxx Consulting

    - Dilip G Shah, CEO of Vision Consulting Group and a regulatory expert

    - Vijay Shah, COO at Piramal Enterprises and pharma business lead

    CPhI Worldwide [http://www.cphi.com ], organised by UBM Live, announces its

initial line-up of confirmed expert industry panel members for 2014 - building

on the huge success of the CPhI annual report launched at CPhI Worldwide in

October 2013.

    (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a )

    This year's panel sees the return of nine thought leaders, with further

members joining imminently. Additionally, this year panel members will also be

utilising their market insights and analysis year-round in the CPhI Pharma

Insights series, which covers individual topics and developments across the

industry - including the recently launched R&D and manufacturing reports.

    Expertise ranges from API and manufacturing efficiencies (Girish Malhotra)

to quality systems and supply chain activities (Sam Venugopal), with insights

also provided from some of the sectors' biggest names and innovators, like

Piramal's Vijay Shah. In addition, the panel features regulatory heavyweight

Ajaz Hussain of Wockhardt - renowned for coining the term PAT - who will lend

his expertise on establishing and improving drug regulation. Across supply

chain issues, the panel will leverage the knowledge of Hedley Rees, whilst

Prabir Basu, formerly of the National Institute for Pharmaceutical Technology

and Education (NIPTE), will focus on the industry's approach to innovation.

    Regulatory expert, predominantly focussed on the Indian market, Dilip Shah

also returns, covering the intellectual property rules around innovation.

    Emil Ciurczak, also previously a member of the FDA's PAT committee and

president of Doramaxx Consulting

[http://www.linkedin.com/search?search=&company=Doramaxx+Consulting&sortCriteria

=R&keepFacets=true&trk=prof-exp-company-name ] , draws up his expertise across

PAT, QbD and spectroscopy. Finally, William Botha, a respected trainer and

mentor in manufacturing, is also retuning to the panel; he is fluent in FDA

regulations, including GDP and GMP.

    Last year's report examined a number of major issues and developments

across the industry including cost savings through QbD and PAT, to regulatory

challenges from a globalised industry, right through to the effect breakthrough

drugs like ADCs will have on overcoming future disease pathologies.

    "Last year's report was a huge success with our experts, providing a

combined insight into the overall picture of the industry. What is interesting

this year is to see the progress the industry has made, and what new problems

or challenges there are. In the first annual report insights spanned a mixture

of practical manufacturing improvements, like single-use reactors and

continuous processing, mixed with regulatory risks and the future potential of

breakthrough drugs like ADCs and supply chain issues. Everything from

life-saving drugs to an open assessment of where industry risks lay, and

culminating in the new business model emerging- with increased partnerships,

innovation sharing and consolidation. Further, our experts offered conclusions

on the necessary techniques, technologies and a simplified regulatory approach

that will simultaneously increase safety and innovation," commented Chris

Kilbee, Group Director Pharma at CPhI.

    The 2014 annual report will feature a collection of in-depth essays from

each panel member - with experts given carte blanche to prophesize how the

industry will look and operate in the future from both an economic and

practical perspective. Additionally, the CPhI Pharma Insights reports contain a

mixture of primary data (industry surveys) and expert comment on what these

findings show about the general direction of the industry and any issues they

feel need to be addressed.

    CPhI is now in the later stages of assembling the panel's full line-up and

plans to announce all participants in the summer - with a few more global

heavyweights expected.

    Kilbee added: "I am delighted that we have been able to source so many

leading figures from within the industry to take part in the panel, as

collectively they bring a huge amount of experience and insight. Already the

panel's knowledge spans pharmaceutical ingredients, manufacturing processes,

global supply chain issues and regulatory frameworks. One thing they all have

in common is a wealth of experience across international markets and a

practical approach to problem solving, which will be invaluable in postulating

future market dynamics."

    For more information, please contact: cphi@ubm.com

    About CPhI

    CPhI drives growth and innovation at every step of the global

pharmaceutical supply chain from drug discovery to finished dosage. Through

exhibitions, conferences and online communities, CPhI brings together more than

100,000 pharmaceutical professionals each year to network, identify business

opportunities and expand the global market. CPhI hosts events in Europe, China,

India, Japan, Southeast Asia, Istanbul, Russia and South America and co-locates

with ICSE for contract services, P-MEC for machinery, equipment & technology,

InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an

online buyer & supplier directory at CPhI-Online.com.

    For more information visit: http://www.cphi.com

    The UBM Live annual schedule of Pharmaceutical events also includes CPhI

Russia and IPhEB (16-17 April, 2014 at the Lenexpo Exhibition Complex- St

Petersburg, Russia); CPhI, P-MEC and Innopack South East Asia (20-22 May, 2014

at the Jakarta International Expo- Jakarta, Indonesia); CPhI Istanbul (4-6

June, 2014, at the Lutfi Kirdar Convention and Exhibition Centre- Turkey);

CPhI, Hi and Fi, ICSE, P-MEC, BioPh and LabWorld China (26-28 June, 2014 at

SNIEC- Shanghai, China); CPhI South America (5-7 August 2014 at Expo Centre

Norte, Sao Paulo- Brazil); CPhI, ICSE Korea (2-3 September, 2014 at the COEX-

Seoul, South Korea); CPhI, ICSE, P-MEC and InnoPack Worldwide (7-9 October

2014, Paris Nord Villepinte- France); CPhI and P-MEC India (2-4 December, 2014

at the Bombay Exhibition Centre- Mumbai); CPhI, ICSE, P-MEC, BioPh and

Pharmatec Japan (22-24 April, 2015 at the Big Sight Exhibition Centre- Tokyo).

    About UBM Live

    UBM Live connects people and creates opportunities for companies across

five continents to develop new business, meet customers, launch new products,

promote their brands, and expand their market. Through premier brands such as

TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete

Show, and many others, UBM Live exhibitions, conferences, awards programs,

publications, Websites, and training and certification programs are an integral

part of the marketing plans of companies across more than 20 industry sectors.

    For media enquiries, please contact:

    Alex Heeley or Tristan Jervis

    De Facto Communications  

    T: +44(0)207-203-6745 / 6740

    E: a.heeley@defacto.com / t.jervis@defacto.com

    SOURCE: UBM Live